E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers P > Headlines for Protalix Biotherapeutics, Inc. > News item
Published on 9/25/2009 in the Prospect News Special Situations Daily.

Protalix Biotherapeutics investor sells more than 2.18 million shares

By Lisa Kerner

Charlotte, N.C., Sept. 25 - Phillip Frost sold 2,181,106 shares of Protalix Biotherapeutics, Inc. between July 24 and Sept. 16 priced from $6.01 to $7.55 each, according to a schedule 13D/A filed on Friday with the Securities and Exchange Commission.

The investor beneficially owns 7,600,167 shares, or 9.9%, of the Carmiel, Israel, biopharmaceutical company.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.